Structure Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 8, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 8, 2024

GPCR$21.73+1.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)




· · · YEAR ENDED DECEMBER 31,
· · 2023 · 2022
Operating expenses: · · · ·
Research and development	$70,103	$36,193
General and administrative	32,672	16,368
Total operating expenses	102,775	52,561
Loss from operations	(102,775)	(52,561)
Interest and other income (expense), net	13,391	1,257
Loss before provision for income taxes	(89,384)	(51,304)
Provision for income taxes	236	17
Net loss	(89,620)	(51,321)
Less: Accretion of redeemable convertible preferred shares to their redemption value	—	(1,515)
Net loss attributable to ordinary shareholders	$(89,620)	$(52,836)
Net loss per share attributable to ordinary shareholders, basic and diluted	$(0.81)	$(5.51)
Weighted-average ordinary shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted	110,198	9,584
Other comprehensive loss:
Unrealized gain (loss) on investments, net	631	(110)
Total other comprehensive income (loss)	631	(110)
Comprehensive loss	$(88,989)	$(51,431)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.